This is a report of the second known case of a primary malignant granular-cell tumor of the cerebral hemispherical white matter. Two cell types may be distinguished apparently representing different developmental stages of otherwise identical tumor cells. Quantitative histochemical and biochemical studies have shown that tumor cells were containing markedly elevated levels of DNA and RNA. Only few ribosomes and polysomes could be detected, however, by electron microscopy. While cytophotometry disclosed only slightly elevated cytoplasmic proteins, there was a distinct increase in total protein concentration of tumor tissue per unit weight, as measured by conventional techniques. It is suggested that this increase is mainly attributable to structural proteins of cellular and subcellular elements of multiplicating malignant cells. A ratio of RNA to DNA in excess of 1 was found for white matter derived from the central tumor, while the ratios of control tissue were lowered to values far below one due to postmortem changes greatly reducing tissue concentrations of RNA. No detailed characterization of RNA was attempted. The nuclear DNA content of tumor cells reached values equivalent to chromosomal hexadekaploidy. This was in sharp contrast to control data from an Abrikossoff tumor of the oral cavity and from a neurohypophyseal tumorette ("choristoma"), respectively, displaying diploidy only associated with a much lesser increase of cytoplasmic RNA and proteins. Qualitative lipid studies were consistent with a marked active demyelination of the tumor centre as indicated by a severe reduction of cerebrosides and sulfatides and the presence of cholesterol esters. In addition there was a striking loss of phosphatidylethanolamine and a lesser one of sphingomyelin of white matter of both the tumor-stricken and the contralateral unaffected hemispherical regions, possibly suggesting a generally disturbed metabolism of myelin. It is not clear whether these general changes were resulting from the presence of the unilateral tumor or from precocious cerebral involution.

Download full-text PDF

Source
http://dx.doi.org/10.1007/BF00689568DOI Listing

Publication Analysis

Top Keywords

white matter
16
tumor cells
12
tumor
10
granular-cell tumor
8
tumor cerebral
8
rna
5
[malignant granular-cell
4
white
4
cerebral white
4
matter
4

Similar Publications

Survivors of pediatric brain tumours are at a high risk of cognitive morbidity. Reliable individual-level predictions regarding the likelihood, degree, and affected domains of cognitive impairment would be clinically beneficial. While established risk factors exist, quantitative MRI analysis may enhance predictive value, above and beyond current clinical risk models.

View Article and Find Full Text PDF

A Framework for Assessing Viral Pathogens: A Key Element of the BARDA Emerging Infectious Diseases Strategy.

Health Secur

January 2025

Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Division of Research, Innovation, and Ventures; and Robert A. Johnson, PhD, is Director, Medical Countermeasures Program; all at the Biomedical Advanced Research and Development Authority, Washington, DC. Gerald R. Kovacs, PhD, is a Senior Advisor; Huyen Cao, MD, is a Senior Clinical Studies Analyst; Christopher Dale, PhD, and Mark Michalik, MBA, are Senior Subject Matter Experts; Mario H. Skiadopoulos, PhD, is a Preclinical Drug Development Subject Matter Expert; and Xiaomi Tong, PhD, is a Senior Regulatory Affairs Subject Matter Expert; all at Tunnell Government Services, Berwyn, PA. Suchismita Chandran, PhD, is a Lead Associate, and Michael Rowe, MS, is a Senior Consultant; both at Booz Allen Hamilton, McLean, VA. Ethan J. Fritch, PhD, is an ORISE Fellow, Oak Ridge Institute for Science and Education, Oak Ridge, TN. George Robertson, PhD, is Chief Scientific Officer, Cambra Consulting, Inc., Woodbridge, VA.

The COVID-19 pandemic has revealed the need for nations to prepare more effectively for emerging infectious diseases. Preparing for these threats requires a multifaceted approach that includes assessing pathogen threat, building flexible capabilities for rapid medical countermeasure (MCM) development, and exercising, maintaining, and improving those response capabilities. The Biomedical Advanced Research and Development Authority (BARDA) promotes the advanced development of MCMs in response to natural and manmade threats.

View Article and Find Full Text PDF

Cerebral autosomal-dominant arteriopathy, subcortical infarcts, and leukoencephalopathy (CADASIL) is the most prevalent monogenic inherited cause of cerebral small-vessel disease. Despite its prevalence, there is currently no proven therapy to prevent or reverse the progression of the disease. This study aimed to characterize the functional integrity of long white matter tracts in CADASIL transgenic mice, both with and without focal white matter lesions in the corpus callosum added on, utilizing optical resting-state functional connectivity imaging alongside behavioral examinations.

View Article and Find Full Text PDF

Cortical Neurotransmitters Measured by Magnetic Resonance Spectroscopy Change Following Traumatic Brachial Plexus Injury.

J Brachial Plex Peripher Nerve Inj

January 2025

School of Health Sciences, Manchester Academic Health Science Centre, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.

 GABA (γ-aminobutyric acid) is the major inhibitory neurotransmitter in the brain. In response to injury within the central nervous system, GABA promotes cortical plasticity and represents a potential pharmacological target to improve functional recovery. However, it is unclear how GABA changes in the brain after traumatic brachial plexus injuries (tBPIs) which represents the rationale for this pilot study.

View Article and Find Full Text PDF

Multidimensional structural analyses revealed a correlation between thalamic atrophy and white matter degeneration in idiopathic dystonia.

Brain Commun

January 2025

Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Guangzhou 510080, China.

Although aberrant changes in grey and white matter are core features of idiopathic dystonia, few studies have explored the correlation between grey and white matter changes in this disease. This study aimed to investigate the coupling correlation between morphological and microstructural alterations in patients with idiopathic dystonia. Structural T1 imaging and diffusion tensor imaging were performed on a relatively large cohort of patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!